Helicobacter Pylori Immune Thrombocytopenic Purpura

Inclusion Criteria: * 20\~55 years old * Persistent or chronic ITP patients, defined by international working group ( persistent: between 3 to 12 months from diagnosis, chronic: lasting for more than 12 months) * 30X109/L ≤ platelet count ≤ 70X109/L * C13-urea breath test: positive * no previous ITP treatment * no previous H. pylori eradication treatment * Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital Exclusion Criteria: * Patients who have any cause of thrombocytopenia such as HIV, HCV infection, lymphoproliferative disease, liver disease, definite SLE, drug, MDS, leukemia * Uncontrolled hypothyroidism or hyperthyroidism * Acute active bleeding or infection * Who taking anti-coagulant or aspirin * Patients with penicillin allergy * Patients with side effects of macrolide. * Patients who taking Mizolastine, Terfenadine, Cisapride, Pimozide, Astemizole, Ergot alkaloid and its derivatives (Ergotamine, Dihydroergotamine), Bepridil, or Atazanavir * Patients who have known allergy or severe side effect on study drugs * Pregnant or lactating women * Clinically relevant hepatic or renal disease (Creatinine clearance ≤ 30mL/min) * patients who cannot understand informed consent or express his/her condition